Level C· Early human research exploring benefitsProspective StudyPubMed

Stem cells derived from osteoarthritic knee mesenchymal tissues: a pilot study.

Labusca LS., Botez P., Zugun Eloae F., Mashayekhi K.

Prospective Study on Osteoarthritis, Cartilage Damage, published in Eur J Orthop Surg Traumatol (2012) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Eur J Orthop Surg Traumatol (2012)
Country
France
Reported sample size
—
Source database
PubMed
PMID
23412448
DOI
10.1007/s00590-012-0949-4

Abstract (original English)

Regenerative medicine is a promising approach for addressing musculoskeletal disorders. Successful implementation of regenerative therapies is based upon existence of reliable, easy accessible cell sources. Mesenchymal tissues removed during total knee replacement (TKR) were investigated as a potential autologous stem cell source. Materials and methods Samples were collected from patients undergoing primary TKR mononuclear cells from adipose and synovial tissue; subchondral trabecular bone and osteoarthritic cartilage were isolated and assessed in terms of mesenchymal stem cells (MSC) content. Results MSCs obtained from all the investigated tissue types and from all donors showed proliferative, differentiation and surface markers characteristic of stemness. Important number of MSCs could be obtained in the first passage (P0). Mesenchymal tissues removed during TJR can qualitatively and quantitatively function as autologous MSC sources to be considered for regenerative therapies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAgedAged, 80 and overArthroplasty, Replacement, KneeCartilage, ArticularCell CountCells, CulturedFemaleHumansKnee Joint

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research